Aura Biosciences Future Growth

Future criteria checks 0/6

Aura Biosciences's earnings are forecast to decline at 8.9% per annum while its annual revenue is expected to grow at 80.1% per year. EPS is expected to decline by 5.4% per annum.

Key information

-8.9%

Earnings growth rate

-5.4%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	80.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	06 Dec 2024

Recent future growth updates

No updates

Recent updates

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10

Earnings and Revenue Growth Forecasts

NasdaqGM:AURA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-120	-156	-106	5
12/31/2025	N/A	-100	-109	-85	6
12/31/2024	N/A	-83	-81	-77	6
9/30/2024	N/A	-83	-75	-73	N/A
6/30/2024	N/A	-81	-74	-73	N/A
3/31/2024	N/A	-79	-73	-72	N/A
12/31/2023	N/A	-76	-65	-64	N/A
9/30/2023	N/A	-71	-65	-64	N/A
6/30/2023	N/A	-68	-61	-60	N/A
3/31/2023	N/A	-63	-56	-56	N/A
12/31/2022	N/A	-59	-56	-55	N/A
9/30/2022	N/A	-55	-50	-49	N/A
6/30/2022	N/A	-52	-49	-47	N/A
3/31/2022	N/A	-51	-45	-42	N/A
12/31/2021	N/A	-46	-35	-32	N/A
9/30/2021	N/A	-40	-26	-24	N/A
6/30/2021	N/A	-33	-23	-22	N/A
3/31/2021	N/A	-29	-22	-21	N/A
12/31/2020	N/A	-30	-25	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AURA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AURA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AURA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AURA is forecast to have no revenue next year.

High Growth Revenue: AURA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AURA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 09:36
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Liisa Bayko	Evercore ISI
Edward White	H.C. Wainwright & Co.
Jonathan Wolleben	JMP Securities

Aura Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Aura Biosciences, Inc. Announces Positive Early Data from an Ongoing Phase 1 Clinical Trial of Bel-sar (AU-011) in Patients with NMIBC

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences, Inc. Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as A First- Line Treatment for Early-Stage Choroidal Melanoma

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Insider selling

Founder recently sold US$121k worth of stock

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Independent Chairman of the Board recently bought US$1.4m worth of stock

Founder notifies of intention to sell stock

Aura Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $99 million.

Aura Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Founder recently sold US$65k worth of stock

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Independent Chairman of the Board recently bought US$168k worth of stock

Aura Biosciences, Inc. Announces Executive Changes

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting

Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Value Index

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AUu-011) Versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences Present Updates Belzupacap Sarotalocan (Au-011) Data on Multiple Studies At the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Independent Chairman of the Board recently bought US$716k worth of stock

Aura Biosciences, Inc. Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences, Inc. Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources